[1]倪佳英,苏青.过氧化物酶体增殖物激活受体激动剂在非酒精性脂肪性肝炎治疗中的研究进展[J].国际内分泌代谢杂志,2022,42(05):377-381.[doi:10.3760/cma.j.cn121383-20210407-04013]
　Ni Jiaying,Su Qing..Advances of peroxisome proliferator-activated receptors agonists in the treatment of non-alcoholic steatohepatitis[J].International Journal of Endocrinology and Metabolism,2022,42(05):377-381.[doi:10.3760/cma.j.cn121383-20210407-04013]
点击复制

过氧化物酶体增殖物激活受体激动剂在非酒精性脂肪性肝炎治疗中的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年05期
页码:
377-381
栏目:
综述
出版日期:
2022-09-20

文章信息/Info

Title:
Advances of peroxisome proliferator-activated receptors agonists in the treatment of non-alcoholic steatohepatitis
作者:
倪佳英; 苏青
上海交通大学医学院附属新华医院内分泌科 200092
Author(s):
Ni Jiaying;  Su Qing.
Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
关键词:
非酒精性脂肪性肝炎;  过氧化物酶体增殖物激活受体;  激动剂
Keywords:
Non-alcoholic steatohepatitis;  Peroxisome proliferator-activated receptors;  Agonists
DOI:
10.3760/cma.j.cn121383-20210407-04013
摘要:
非酒精性脂肪性肝炎(NASH)是非酒精性脂肪性肝病(NAFLD)中较为严重的亚型。其特征是肝脏脂肪变性、炎症和纤维化。过氧化物酶体增殖物激活受体(PPARs)是一类由配体激活的核转录因子,包括PPARα、PPARβ/δ和PPARγ 3种类型。PPARs作为脂质代谢、葡萄糖稳态和炎症的重要调节因子,已成为NASH治疗的潜在靶点。近年来,越来越多的研究表明PPARs激动剂在动物实验中可见NASH组织学的改善,显示出巨大优势。PPARs激动剂在临床试验中的证据也不断涌现,有望在NAFLD/NASH的治疗中发挥重要作用。
Abstract:
Non-alcoholic steatohepatitis(NASH)is the severer subtype of non-alcoholic fatty liver disease(NAFLD). It is characterized by hepatic steatosis, inflammation and fibrosis. Peroxisome proliferator-activated receptors(PPARs)are a class of ligand-activated nuclear transcription factors, including PPARα, PPARβ/δ, and PPARγ. As important regulators of lipid metabolism, glucose homeostasis, and inflammation, PPARs have become potential targets for NASH therapy. In recent years, more and more studies have shown that PPARs agonists can improve NASH histology in animal experiments, showing great advantages. Evidence of PPARs agonists in clinical trials has also sprouted, which make them a promising agent in the treatment of NAFLD/NASH.

参考文献/References:

[1] Sheka AC,Adeyi O,Thompson J,et al.Nonalcoholic steatohepatitis:a review[J].JAMA,2020,323(12):1175-1183.DOI:10.1001/jama.2020.2298.
[2] Choudhary NS,Kumar N,Duseja A.Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease[J].J Clin Exp Hepatol,2019,9(6):731-739.DOI:10.1016/j.jceh.2019.06.004.
[3] Day CP,James OF.Steatohepatitis:a tale of two "hits"?[J].Gastroenterology,1998,114(4):842-845.DOI:10.1016/s0016-5085(98)70599-2.
[4] Buzzetti E,Pinzani M,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J].Metabolism,2016,65(8):1038-1048.DOI:10.1016/j.metabol.2015.12.012.
[5] Pawlak M,Lefebvre P,Staels B.Molecular mechanism of PPARα action and its impact on lipid metabolism,inflammation and fibrosis in non-alcoholic fatty liver disease[J].J Hepatol,2015,62(3):720-733.DOI:10.1016/j.jhep.2014.10.039.
[6] Luo W,Xu Q,Wang Q,et al.Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease[J].Sci Rep,2017,7:44612.DOI:10.1038/srep44612.
[7] Odegaard JI,Ricardo-Gonzalez RR,Red Eagle A,et al.Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance[J].Cell Metab,2008,7(6):496-507.DOI:10.1016/j.cmet.2008.04.003.
[8] Ni XX,Li XY,Wang Q,et al.Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway[J].J Physiol Biochem,2021,77(1):35-45.DOI:10.1007/s13105-020-00777-7.
[9] 饶慧瑛,魏来.非酒精性脂肪性肝炎治疗药物临床试验指南解读[J].临床肝胆病杂志,2021,37(6):1245-1248.DOI:10.3969/j.issn.1001-5256.2021.06.002.
[10] Ishibashi S,Arai H,Yokote K,et al.Efficacy and safety of pemafibrate(K-877),a selective peroxisome proliferator-activated receptor α modulator,in patients with dyslipidemia:results from a 24-week,randomized,double blind,active-controlled,phase 3 trial[J].J Clin Lipidol,2018,12(1):173-184.DOI:10.1016/j.jacl.2017.10.006.
[11] Sasaki Y,Asahiyama M,Tanaka T,et al.Pemafibrate,a selective PPARα modulator,prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content[J].Sci Rep,2020,10(1):7818.DOI:10.1038/s41598-020-64902-8.
[12] Nakajima A,Eguchi Y,Yoneda M,et al.Randomised clinical trial:Pemafibrate,a novel selective peroxisome proliferator-activated receptor α modulator(SPPARMα),versus placebo in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2021,54(10):1263-1277.DOI:10.1111/apt.16596.
[13] Haczeyni F,Wang H,Barn V,et al.The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice[J].Hepatol Commun,2017,1(7):663-674.DOI:10.1002/hep4.1072.
[14] 孙超,范建高.2020年非酒精性脂肪性肝病的更名及诊疗进展回顾[J].中华医学信息导报,2021,36(1):6-7.DOI:10.3760/cma.j.issn.1000-8039.2021.01.105.
[15] Kalavalapalli S,Bril F,Koelmel JP,et al.Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis[J].Am J Physiol Endocrinol Metab,2018,315(2):E163-e173.DOI:10.1152/ajpendo.00023.2018.
[16] Cusi K,Orsak B,Bril F,et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus:a randomized trial[J].Ann Intern Med,2016,165(5):305-315.DOI:10.7326/M15-1774.
[17] Harrison SA,Alkhouri N,Davison BA,et al.Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis:a randomized,double-blind,placebo-controlled phase IIb study[J].J Hepatol,2020,72(4):613-626.DOI:10.1016/j.jhep.2019.10.023.
[18] Jain MR,Giri SR,Bhoi B,et al.Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models[J].Liver Int,2018,38(6):1084-1094.DOI:10.1111/liv.13634.
[19] Gawrieh S,Noureddin M,Loo N,et al.Saroglitazar,a PPAR-α/γ agonist,for treatment of NAFLD:a randomized controlled double-blind phase 2 trial[J].Hepatology,2021,74(4):1809-1824.DOI:10.1002/hep.31843.
[20] Kalliora C,Drosatos K.The glitazars paradox:cardiotoxicity of the metabolically beneficial dual PPARα and PPARγ activation[J].J Cardiovasc Pharmacol,2020,76(5):514-526.DOI:10.1097/FJC.0000000000000891.
[21] Briand F,Heymes C,Bonada L,et al.A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death[J].Clin Transl Sci,2020,13(3):529-538.DOI:10.1111/cts.12735.
[22] Ratziu V,Harrison SA,Francque S,et al.Elafibranor,an agonist of the peroxisome proliferator-activated receptor-α and -δ,induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J].Gastroenterology,2016,150(5):1147-1159.e5.DOI:10.1053/j.gastro.2016.01.038.
[23] Lefere S,Puengel T,Hundertmark J,et al.Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages[J].J Hepatol,2020,73(4):757-770.DOI:10.1016/j.jhep.2020.04.025.
[24] Boyer-Diaz Z,Aristu-Zabalza P,Andrés-Rozas M,et al.Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease[J].J Hepatol,2020,74(5):1188-1199.DOI:10.1016/j.jhep.2020.11.045.
[25] Francque SM,Bedossa P,Ratziu V,et al.A randomized,controlled trial of the pan-PPAR agonist lanifibranor in NASH[J].N Engl J Med,2021,385(17):1547-1558.DOI:10.1056/NEJMoa2036205.

相似文献/References:

[1]张晓燕,陈莉明.儿童非酒精性脂肪性肝病研究进展[J].国际内分泌代谢杂志,2007,(04):289.

备注/Memo

备注/Memo:
通信作者:苏青,Email: suqing139@126.com
基金项目:国家自然科学基金(81970669)
更新日期/Last Update: 2022-09-10